EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

In silico approaches supporting drug repurposing for Leishmaniasis

Gustavo Scheiffer, Karime Zeraik Abdalla Domingues, Daniela Gorski, Alexandre de Fátima Cobre, Raul Edison Luna Lazo, Helena Hiemisch Lobo Borba, Luana Mota Ferreira, Roberto Pontarolo

EXCLI Journal · 03.09.2024 · 23 · 1117-1169

DOI: 10.17179/excli2024-7552 ↗

Kurz gefasst

Scoping Review in der Zeitschrift EXCLI Journal, online erschienen am 03.09.2024. Verfasst von Gustavo Scheiffer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Paraná, Curitiba 80210-170, Paraná, Brazil. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The shortage of treatment options for leishmaniasis, especially those easy to administer and viable for deployment in the world's poorest regions, highlights the importance of employing these strategies to cost-effectively investigate repurposing candidates. This scoping review aims to map the studies using in silico methodologies for drug repurposing against leishmaniasis. This study followed JBI recommendations for scoping reviews. Articles were searched on PubMed, Scopus, and Web of Science databases using keywords related to leishmaniasis and in silico methods for drug discovery, without publication date restrictions. The selection was based on primary studies involving computational methods for antileishmanial drug repurposing. Information about methodologies, obtained data, and outcomes were extracted. After the full-text appraisal, 34 studies were included in this review. Molecular docking was the preferred method for evaluating repurposing candidates (n=25). Studies reported 154 unique ligands and 72 different targets, sterol 14-alpha demethylase and trypanothione reductase being the most frequently reported. In silico screening was able to correctly pinpoint some known active pharmaceutical classes and propose previously untested drugs. Fifteen drugs investigated in silico exhibited low micromolar inhibition (IC50 < 10 µM) of Leishmania spp. in vitro. In conclusion, several in silico repurposing candidates are yet to be investigated in vitro and in vivo. Future research could expand the number of targets screened and employ advanced methods to optimize drug selection, offering new starting points for treatment development.

Schlagwörter

Stichwörter der Autor:innen

computer-aided drug designdockinggenomicsmolecular dynamicsneglected tropical diseasesrepositioning

Autor:innen und Institutionen

  • Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Paraná, Curitiba 80210-170, Paraná, Brazil.

Zitieren

APA

Scheiffer, G., Domingues, K. Z. A., Gorski, D., Cobre, A. F., Lazo, R. E. L., Borba, H. H. L., Ferreira, L. M., & Pontarolo, R. (2024). In silico approaches supporting drug repurposing for Leishmaniasis. EXCLI Journal, 23, 1117-1169. https://doi.org/10.17179/excli2024-7552

Vancouver

Scheiffer G, Domingues KZA, Gorski D, Cobre AF, Lazo REL, Borba HHL, et al. In silico approaches supporting drug repurposing for Leishmaniasis. EXCLI Journal. 2024;23:1117-1169. doi:10.17179/excli2024-7552

BibTeX
@article{Scheiffer2024,
  author = {Scheiffer, Gustavo and Domingues, Karime Zeraik Abdalla and Gorski, Daniela and Cobre, Alexandre de Fátima and Lazo, Raul Edison Luna and Borba, Helena Hiemisch Lobo and Ferreira, Luana Mota and Pontarolo, Roberto},
  title = {In silico approaches supporting drug repurposing for Leishmaniasis},
  journal = {EXCLI Journal},
  year = {2024},
  volume = {23},
  pages = {1117--1169},
  doi = {10.17179/excli2024-7552}
}
Kostenlos starten →